Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

In this MEDtalk Dr. Gabriel Brisou shares findings from the Descartes registry on the use of axi-cel (CAR-T cell therapy) for treating patients with large B-cell lymphoma in a second-line setting. Since July 2022, over 200 patients in France have been treated, showing an overall response rate of around 80% and 66% achieving complete remission. Despite a short median follow-up time of three months, the early data suggest efficacy comparable to previous trials, offering new opportunities for patients unresponsive to initial therapies.